Publications by authors named "Nathalie Adda"

Claim this Profile
E
EDP-297: A novel, farnesoid X receptor agonist-Results of a phase I study in healthy subjects.
Christine Marotta, Alaa Ahmad, Ed Luo, Jart Oosterhaven, Sjoerd van Marle, Nathalie Adda

Clin Transl Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.
Jordan J Feld, Eric Lawitz, Tuan Nguyen, Jacob Lalezari, Tarek Hassanein, Nathalie Adda

Antivir Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects.
Alaa Ahmad, Nathalie Adda

Clin Transl Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
Vlad Ratziu, Mary E Rinella, Brent A Neuschwander-Tetri, Eric Lawitz, Douglas Denham, Nathalie Adda

J Hepatol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Alaa Ahmad, Kingsley Eze, Nicolas Noulin, Veronika Horvathova, Bryan Murray, Nathalie Adda

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial.
Fabien Zoulim, Claire Fournier, François Habersetzer, Martin Sprinzl, Stanislas Pol, Nathalie Adda

Hum Vaccin Immunother· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.
Steven L Flamm, Andrew J Muir, Michael W Fried, K Rajender Reddy, David R Nelson, Nathalie Adda

J Clin Gastroenterol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.
Gaston Picchio, Sandra De Meyer, Inge Dierynck, Anne Ghys, Linda Gritz, Nathalie Adda

J Clin Virol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.
James C Sullivan, Sandra De Meyer, Doug J Bartels, Inge Dierynck, Eileen Z Zhang, Nathalie Adda

Clin Infect Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
Mark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, Mohammad Bsharat, Lisa Mahnke, Nathalie Adda

Ann Intern Med· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Varun Garg, Gurudatt Chandorkar, Yijun Yang, Nathalie Adda, Lindsay McNair

Br J Clin Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
Nathalie Adda, Doug J Bartels, Linda Gritz, Tara L Kieffer, Frank Tomaka

Clin Gastroenterol Hepatol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Nathalie Adda

PLoS One· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir.
Varun Garg, Rolf van Heeswijk, Yijun Yang, Robert Kauffman, Frances Smith, Nathalie Adda

J Clin Pharmacol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
Andrew J Muir, Fred F Poordad, John G McHutchison, Mitchell L Shiffman, Thomas Berg, Nathalie Adda

Hepatology· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-guided telaprevir combination treatment for hepatitis C virus infection.
Kenneth E Sherman, Steven L Flamm, Nezam H Afdhal, David R Nelson, Mark S Sulkowski, Nathalie Adda

N Engl J Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir for previously untreated chronic hepatitis C virus infection.
Ira M Jacobson, John G McHutchison, Geoffrey Dusheiko, Adrian M Di Bisceglie, K Rajender Reddy, Nathalie Adda

N Engl J Med· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir for previously treated chronic HCV infection.
John G McHutchison, Michael P Manns, Andrew J Muir, Norah A Terrault, Ira M Jacobson, Nathalie Adda

N Engl J Med· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.
Xavier Saez-Llorens, Avy Violari, Dalubuhle Ndiweni, Ram Yogev, Miguel Cashat, Nathalie Adda

Pediatrics· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
Gregory E Chittick, Jian Zong, M Robert Blum, Jeffrey J Sorbel, John A Begley, Nathalie Adda

Antimicrob Agents Chemother· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.
Melanie A Thompson, Harold A Kessler, Joseph J Eron, Jeffrey M Jacobson, Nathalie Adda

AIDS· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis